Skip to main content
Top
Published in: Rheumatology International 5/2021

Open Access 01-05-2021 | Rheumatoid Arthritis | Patient Opinion

Patient perspectives on how to improve education on medication side effects: cross-sectional observational study at a rheumatology clinic in The Netherlands

Authors: Mirjam C. Hegeman, Jolanda A. Schoemaker-Delsing, Jacqueline T. M. Luttikholt, Harald E. Vonkeman

Published in: Rheumatology International | Issue 5/2021

Login to get access

Abstract

Rheumatoid arthritis (RA) patients often report lacking information on medication side effects. The aims of this study were to observe how rheumatology healthcare providers deliver medication information and to determine in which specific domains information is missing. First, 12 single-blinded structured observations were performed during regular RA patient consultations. The observers noted whether and how medication and medication side effects were discussed. Second, 100 RA patients were asked to fill out an adaptation of the Satisfaction with Information about Medicines Scale (SIMS). Medication was discussed during all observed consultations. With new medication, its purpose and mode of action were explained in all cases, but possible side effects in only 33%. Overall, medication side effects were discussed in 58% of consultations. Most information delivery was verbal (92%). Response rate to the questionnaire was 61%. Overall satisfaction with medication education was mean 7.3 (± 1.9) (NRS 0–10) with a comparable high SIMS total satisfaction sum score of mean 12.3 (± 4.4). At subscale score levels, 89% were satisfied with the amount of information on the action and usage of medication, but only 47% with the information on the potential problems of medication. RA patients express overall high satisfaction with their medication education but there is still an unmet need for information on potential risks and side effects. Using the SIMS questionnaire in daily clinical practice may help focus medication education to the needs of the individual patient.
Appendix
Available only for authorised users
Literature
4.
go back to reference Quinn MA, Emery P (2003) Window of opportunity in early rheumatoid arthritis: possibility of altering the disease process with early intervention. Clin Exp Rheumatol 21(5 Suppl 31):S154–S157PubMed Quinn MA, Emery P (2003) Window of opportunity in early rheumatoid arthritis: possibility of altering the disease process with early intervention. Clin Exp Rheumatol 21(5 Suppl 31):S154–S157PubMed
7.
go back to reference Steunebrink LMM, Versteeg GA, Vonkeman HE, ten Klooster PM, Kuper HH, Zijlstra TR, van Riel PCLM, van de Laar MAFJ (2016) Initial combination therapy versus step-up therapy in treatment to the target of remission in daily clinical practice in early rheumatoid arthritis patients: results from the DREAM registry. Arthritis Res Ther 8(18):60. https://doi.org/10.1186/s13075-016-0962-9CrossRef Steunebrink LMM, Versteeg GA, Vonkeman HE, ten Klooster PM, Kuper HH, Zijlstra TR, van Riel PCLM, van de Laar MAFJ (2016) Initial combination therapy versus step-up therapy in treatment to the target of remission in daily clinical practice in early rheumatoid arthritis patients: results from the DREAM registry. Arthritis Res Ther 8(18):60. https://​doi.​org/​10.​1186/​s13075-016-0962-9CrossRef
15.
go back to reference Hugtenburg JG, Ilahibaks SS, Borgsteede SD (2008) Voorlichting over geneesmiddelen aan patiënten met diabetes mellitus type 2 moet worden uitgebreid. PW Wetenschappelijk Platform 2(3):50–55 Hugtenburg JG, Ilahibaks SS, Borgsteede SD (2008) Voorlichting over geneesmiddelen aan patiënten met diabetes mellitus type 2 moet worden uitgebreid. PW Wetenschappelijk Platform 2(3):50–55
Metadata
Title
Patient perspectives on how to improve education on medication side effects: cross-sectional observational study at a rheumatology clinic in The Netherlands
Authors
Mirjam C. Hegeman
Jolanda A. Schoemaker-Delsing
Jacqueline T. M. Luttikholt
Harald E. Vonkeman
Publication date
01-05-2021
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 5/2021
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-021-04815-5

Other articles of this Issue 5/2021

Rheumatology International 5/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.